Resources

Breast Cancer

Ki67 Testing

These resources, related to a January 2022 ASCP webinar on Ki67 testing, highlight important and practice-changing developments, such as new clinical data with immediate implications for patient care.

The resources address key educational gaps and controversies related to optimal testing methods, addressing challenges with standardization, interpreting findings, and potential therapeutic implications for patients with HR-positive/HER2-negative early breast cancer to optimize clinical outcomes.

Provided by the American Society for Clinical Pathology in partnership with Clinical Care Options, LLC. This activity is supported by an educational grant from Lilly.

Ki67 Slide Deck (pdf)

Ki67 At-a-glance (pdf) Ki67 Expert Commentary

HER2-low Breast Cancer

This downloadable, easily sharable set of slides is intended for pathologists to use to educate colleagues on HER2-low breast cancer. The slides cover the following topics:

The science of HER2-low breast cancer
Clinical practice guidelines for HER2 testing in patients with breast cancer
Emerging therapies designed to treat patients with HER2-low breast cancer

Provided by the American Society for Clinical Pathology in partnership with Q-Synthesis, LLC and Clinical Care Options, LLC. Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

Download the Slides (ppt)

First Name *
Last Name *
Email *
Customer ID

Name *
Country Code *
Phone Number *
Scheduled Date *
Scheduled Time *
Customer Id